SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats

BMC Neuroscience

T Celeste Napier¹  Steven M Graves¹ 

[1] Center for Compulsive Behavior and Addiction, Rush University Medical Center, 1735 W Harrison Street, Cohn Research Building, Chicago, IL, 60612, USA

关键词: Seeking;    Inverse agonist;    Motor;    Self-administration;    Serotonin;    Methamphetamine;   

Others  :  1170675
DOI  :  10.1186/1471-2202-13-65

 received in 2012-01-10, accepted in 2012-06-01,  发布年份 2012

【 摘 要 】

Background

Methamphetamine (meth) dependence presents a substantial socioeconomic burden. Despite the need, there is no FDA-approved pharmacotherapy for psychostimulant dependence. We consider 5-HT_2C receptors as viable therapeutic targets. We recently revealed that the atypical antidepressant, mirtazapine, attenuates meth-seeking in a rodent model of human substance abuse. Mirtazapine historically has been considered to be an antagonist at 5-HT_2C receptors, but more recently shown to exhibit inverse agonism at constitutively active 5-HT_2C receptors. To help distinguish the roles for antagonism vs. inverse agonism, here we explored the ability of a more selective 5-HT_2C inverse agonist, SB 206553 to attenuate meth-seeking behavior, and compared its effects to those obtained with 5-HT_2C antagonists, SDZ Ser 082 and SB 242084. To do so, rats were trained to self-administer meth and tested for seeking-like behavior in cue reactivity sessions consisting of contingently presenting meth-associated cues without meth reinforcement. We also explored motor function to determine the influence of SB 206553 and SDZ Ser 082 on motor activity in the presence and absence of meth.

Results

Like mirtazapine, pretreatment with SB 206553 (1.0, 5.0, and 10.0 mg/kg), attenuated meth-seeking. In contrast, the antagonists, SDZ Ser 082 (0.1, 0.3, and 1.0 mg/kg) and SB 242084 (3.0 mg/kg) had no effect on cue reactivity (CR). SB 242084 (3.0 mg/kg) failed to attenuate the effects of 5.0 and 10 mg/kg SB 206553 on CR. Motor function was largely unaltered by the 5-HT_2C ligands; however, SB 206553, at the highest dose tested (10.0 mg/kg), attenuated meth-induced rearing behavior.

Conclusions

The lack of effect by 5-HT_2C antagonists suggests that meth-seeking and meth-evoked motor activity are independent of endogenous 5-HT acting at 5-HT_2C receptors. While SB 206553 dramatically impacted meth-evoked behaviors it is unclear whether the observed effects were 5-HT_2C receptor mediated. Thus, SB 206553 deserves further attention in the study of psychostimulant abuse disorders.

【 授权许可】

   
2012 Graves and Napier; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Higgins GA, Fletcher PJ: Serotonin and drug reward: focus on 5-HT2C receptors. Eur J Pharmacol 2003, 480:151-162.
• [2]Hayes DJ, Greenshaw AJ: 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev 2011, 35:1419-1449.
• [3]Fletcher PJ, Grottick AJ, Higgins GA: Differential effects of the 5-HT(2A) receptor antagonost M100,907 and the 5-HT(2 C) receptor antagonist SB242,084 on cocaine-iduced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropschopharmacology 2002, 27:576-586.
• [4]Burbassi S, Cervo L: Stimulation of serotonin2C receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats. Psychopharmacology (Berl) 2008, 196:15-27.
• [5]Neisewander JL, Acosta JI: Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats. Behav Pharmacol 2007, 18:791-800.
• [6]Cunningham KA, Fox RG, Anastasio NC, Bubar MJ, Stutz SJ, Moeller FG, Gilbertson SR, Rosenzweig-Lipson S: Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. Neuropharmacology 2011, 61:513-523.
• [7]Filip M: Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats. Pharmacol Rep 2005, 57:35-46.
• [8]De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U: Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004, 24:3235-3241.
• [9]Leggio GM, Cathala A, Neny M, Rouge-Pont F, Drago F, Piazza PV, Spampinato U: In vivo evidence that constitutive activity of serotonin(2C) receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. J Neurochem 2009.
• [10]Navailles S, Moison D, Ryczko D, Spampinato U: Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. J Neurochem 2006, 99:1311-1319.
• [11]Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB: Regulation of serotonin-2 C receptor G-protein coupling by RNA editing. Nature 1997, 387:303-308.
• [12]Niswender CM, Sanders-Bush E, Emeson RB: Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci 1998, 861:38-48.
• [13]Sanders-Bush E, Fentress H, Hazelwood L: Serotonin 5-ht2 receptors: molecular and genomic diversity. Mol Interv 2003, 3:319-330.
• [14]Werry TD, Loiacono R, Sexton PM, Christopoulos A: RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol Ther 2008, 119:7-23.
• [15]Gardiner K, Du Y: A-to-I editing of the 5HT2C receptor and behaviour. Brief Funct Genomic Proteomic 2006, 5:37-42.
• [16]Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR: Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 1999, 21:82S-90S.
• [17]Herrick-Davis K, Grinde E, Niswender CM: Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 1999, 73:1711-1717.
• [18]Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E: RNA editing of the human serotonin 5-hydroxytryptamine 2 C receptor silences constitutive activity. J Biol Chem 1999, 274:9472-9478.
• [19]Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP: RNA-editing of the 5-HT(2 C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 2001, 134:386-392.
• [20]Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP: A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther 2008, 324:1084-1092.
• [21]Kenakin T: Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2002, 42:349-379.
• [22]Kenakin T: Principles: receptor theory in pharmacology. Trends Pharmacol Sci 2004, 25:186-192.
• [23]Willins DL, Meltzer HY: Serotonin 5-HT2Cagonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Research 1998, 781:291-299.
• [24]Lucas G, Spampinato U: Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 2000, 74:693-701.
• [25]Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Ddhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ: Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 2000, 36:205-221.
• [26]Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E: Selective blockade of serotonin2C/2Breceptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 1998, 37:265-272.
• [27]Di Matteo V, Di Mascio M, Di Giovanni G, Esposito E: Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2Creceptors. Psychopharmacology 2000, 150:45-51.
• [28]McDaid J, Tedford CE, Mackie AR, Dallimore JE, Mickiewicz AL, Shen F, Angle JM, Napier TC: Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats. Drug Alcohol Depend 2007, 86:55-66.
• [29]Voigt RM, Napier TC: Context-dependent effects of a single administration of mirtazapine on the expression of methamphetamine-induced conditioned place preference. Front Behav Neurosci 2011, 5:92.
• [30]Voigt RM, Mickiewicz AL, Napier TC: Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats. Behav Brain Res 2011, 225:91-96.
• [31]Herrold AA, Shen F, Graham MP, Harper LK, Specio SE, Tedford CE, Napier TC: Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend 2009, 99:231-239.
• [32]Kooyman AR, Zwart R, Vanderheijden PM, Van Hooft JA, Vijverberg HP: Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 1994, 33:501-507.
• [33]de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza- analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988, 27:399-408.
• [34]Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2- adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 2000, 12:1079-1095.
• [35]Chanrion B, la Mannoury CC, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ: Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol 2008, 73:748-757.
• [36]Labasque M, Meffre J, Carrat G, Becamel C, Bockaert J, Marin P: Constitutive Activity of Serotonin2C Receptors at G Protein-Independent Signaling: Modulation by RNA Editing and Antidepressants. Mol Pharmacol 2010.
• [37]Graves SM, Napier TC: Mirtazapine alters cue-associated methamphetamine seeking in rats. Biol Psychiatry 2011, 69:275-281.
• [38]Acosta JI, Thiel KJ, Sanabria F, Browning JR, Neisewander JL: Effect of schedule of reinforcement on cue-elicited reinstatement of cocaine-seeking behavior. Behav Pharmacol 2008, 19:129-136.
• [39]Filip M, Bubar MJ, Cunningham KA: Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacology (Berl) 2006, 183:482-489.
• [40]Filip M, Bubar MJ, Cunningham KA: Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther 2004, 310:1246-1254.
• [41]Kourrich S, Thomas MJ: Similar neurons, opposite adaptations: psychostimulant experience differentially alters firing properties in accumbens core versus shell. J Neurosci 2009, 29:12275-12283.
• [42]Rademacher DJ, Napier TC, Meredith GE: Context modulates the expression of conditioned motor sensitization, cellular activation and synaptophysin immunoreactivity. Eur J Neurosci 2007, 26:2661-2668.
• [43]Rademacher DJ, Kovacs B, Shen F, Napier TC, Meredith GE: The neural substrates of amphetamine conditioned place preference: implications for the formation of conditioned stimulus-reward associations. Eur J Neurosci 2006, 24:2089-2097.
• [44]McDaid J, Graham MP, Napier TC: Methamphetamine-induced sensitization differentially alters pCREB and ΔFosB throughtout the limbic circuit of the mammalian brain. Mol Pharmacol 2006, 70:2064-2074.
• [45]Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M: Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2 C) receptors. Naunyn Schmiedebergs Arch Pharmacol 2004, 370:114-123.
• [46]Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, et al.: In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 1996, 117:427-434.
• [47]Auclair AL, Cathala A, Sarrazin F, Depoortere R, Piazza PV, Newman-Tancredi A, Spampinato U: The central serotonin receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 2010, 114:1323-1332.
• [48]Nic Dhonnchadha BA, Fox RG, Stutz SJ, Rice KC, Cunningham KA: Blockade of the serotonin 5-ht2a receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. Behav Neurosci 2009, 123:382-396.
• [49]Porras G, Di MV, Fracasso C, Lucas G, De DP, Caccia S, Esposito E, Spampinato U: 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 2002, 26:311-324.
• [50]Egerton A, Ahmad R, Hirani E, Grasby PM: Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11 C]raclopride PET studies in the rat. Psychopharmacology (Berl) 2008, 200:487-496.
• [51]Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, et al.: Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2 H)-carboxamide). J Pharmacol Exp Ther 2009, 328:766-776.
• [52]Panagis G, Kastellakis A, Spyraki C, Nomikos G: Effects of methyllycaconitine (MLA), an alpha 7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology (Berl) 2000, 149:388-396.
• [53]Hiranita T, Nawata Y, Sakimura K, Anggadiredja K, Yamamoto T: Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A 2006, 103:8523-8527.
• [54]Napier TC, Istre ED: Methamphetamine-induced sensitization includes a functional upregulation of ventral pallidal 5-HT2A/2 C receptors. Synapse 2008, 62:14-21.
• [55]Huang XF, Tan YY, Huang X, Wang Q: Effect of chronic treatment with clozapine and haloperidol on 5-HT(2A and 2 C) receptor mRNA expression in the rat brain. Neurosci Res 2007, 59:314-321.
• [56]Du Y, Stasko M, Costa AC, Davisson MT, Gardiner KJ: Editing of the serotonin 2 C receptor pre-mRNA: Effects of the Morris Water Maze. Gene 2007, 391:186-197.
• [57]Iwamoto K, Nakatani N, Bundo M, Yoshikawa T, Kato T: Altered RNA editing of serotonin 2 C receptor in a rat model of depression. Neurosci Res 2005, 53:69-76.
• [58]Englander MT, Dulawa SC, Bhansali P, Schmauss C: How stress and fluoxetine modulate serotonin 2 C receptor pre-mRNA editing. J Neurosci 2005, 25:648-651.
• [59]McCreary AC, Cunningham KA: Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology 1999, 20:556-564.
• [60]Paterson NE, Froestl W, Markou A: The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 2004, 172:179-186.
• [61]Paterson NE, Markou A: The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology 2004.
• [62]Fletcher PJ, Sinyard J, Higgins GA: Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement. Pharmacol Biochem Behav 2010, 97:170-178.
• [63]Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA: Characterizing the effects of 5-HT(2 C) receptor ligands on motor activity and feeding behaviour in 5-HT(2 C) receptor knockout mice. Neuropharmacology 2009, 57:259-267.
• [64]Hayes DJ, Clements R, Greenshaw AJ: Effects of systemic and intra-nucleus accumbens 5-HT2C receptor compounds on ventral tegmental area self-stimulation thresholds in rats. Psychopharmacology (Berl) 2009, 203:579-588.
• [65]Katsidoni V, Apazoglou K, Panagis G: Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacology (Berl) 2011, 213:337-354.